تثبيط BRAF المُطفَر والمنشط في الورم الميلانيني النقيلي

درس فلاريتي وآخرون (الأربعاء) هذا السؤال.

www.synapsesocial.com/papers/69d6bfdbfca0359822aa831e — DOI: https://doi.org/10.1056/nejmoa1002011

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Mutations of the BRAF gene in human cancer· 2002 · 10,654 citations
2. DTIC (NSC-45388) in malignant melanoma: a perspective.· 1976 · 165 citations
3. Toxicity and response criteria of the Eastern Cooperative Oncology Group· 1982 · 11,559 citations
4. Differential sensitivity of melanoma cell lines with BRAF V600E mutation to the specific Raf inhibitor PLX4032· 2010 · 226 citations
5. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF· 2010 · 1,810 citations